General Recommendations on Immunization
This chapter discusses issues that are commonly encountered in vaccination practice. A more thorough discussion of issues common to more than one vaccine can be found in the General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices. These recommendations are revised every 3–5 years as needed; the most current edition was published in December 2006 (MMWR 2006;55[RR-15]:1–48). All providers who administer vaccine should have a copy of this report and be familiar with its content. It can be downloaded from the MMWR website or ordered in print version from the Centers for Disease Control and Prevention.

Timing and Spacing of Vaccines
The timing and spacing of vaccine doses are two of the most important issues in the appropriate use of vaccines. Specific circumstances that are commonly encountered in immunization practice are the timing of antibody-containing blood products and live vaccines (particularly measles and varicella-containing vaccines), simultaneous and nonsimultaneous administration of different vaccines, and the interval between subsequent doses of the same vaccine.

Antibody–Vaccine Interactions

GENERAL RULE

Inactivated vaccines generally are not affected by circulating antibody to the antigen.

Live attenuated vaccines may be affected by circulating antibody to the antigen.

The presence of circulating antibody to a vaccine antigen may reduce or completely eliminate the immune response to the vaccine. The amount of interference produced by circulating antibody generally depends on the type of vaccine administered and the amount of antibody.

Inactivated antigens are generally not affected by circulating antibody, so they can be administered before, after, or at the same time as the antibody. Simultaneous administration of antibody (in the form of immune globulin) and vaccine is recommended for postexposure prophylaxis of certain diseases, such as hepatitis B, rabies, and tetanus.
Live Injected Vaccines

Live vaccines must replicate in order to cause an immune response. Antibody against injected live vaccine antigen may interfere with replication. If a live injectable vaccine (measles-mumps-rubella [MMR], varicella, or combination measles-mumps-rubella-varicella [MMRV]) must be given around the time that antibody is given, the two must be separated by enough time so that the antibody does not interfere with viral replication. If the live vaccine is given first, it is necessary to wait at least 2 weeks (i.e., an incubation period) before giving the antibody. If the interval between the vaccine and antibody is less than 2 weeks, the recipient should be tested for immunity or the vaccine dose should be repeated.

If the antibody is given before a dose of MMR or varicella vaccine, it is necessary to wait until the antibody has waned (degraded) before giving the vaccine to reduce the chance of interference by the antibody. The necessary interval between an antibody-containing product and MMR or varicella-containing vaccine (except zoster vaccine) depends on the concentration of antibody in the product, but is always 3 months or longer. A table listing the recommended intervals between administration of antibody products and live vaccines (MMR and varicella-containing) is included in Appendix A and in the General Recommendations on Immunization (2006). The interval between administration of an antibody product and MMR or varicella vaccination can be as long as 11 months. Zoster vaccine is not known to be affected by circulating antibody so it can be administered at any time before or after receipt of an antibody-containing blood product.

Although passively acquired antibodies can interfere with the response to rubella vaccine, the low dose of anti-Rho(D) globulin administered to postpartum women has not been demonstrated to reduce the response to the rubella vaccine. Because of the importance of rubella and varicella immunity among childbearing age women, women without evidence of immunity to rubella or varicella should receive single-antigen rubella, MMR, or varicella vaccine (but not MMRV) in the postpartum period. Vaccination should not be delayed because of receipt of anti-Rho(D) globulin or any other blood product during the last trimester of pregnancy or at delivery. These women should be vaccinated immediately after delivery and, if possible, tested 3 months later to ensure immunity to rubella and, if necessary, to measles.

Live Oral and Intranasal Vaccines

Available data suggest that the presence of passive antibody may reduce or blunt the response to live oral rotavirus vaccine. The Advisory Committee on Immunization Practices...
General Recommendations on Immunization

(ACIP) recommends deferral of rotavirus vaccination for 6 weeks after receipt of a blood product if possible. However, if the 6-week deferral would cause the first dose of rotavirus vaccine to be scheduled for 13 weeks of age or older, a shorter deferral interval should be used to ensure the first dose is administered before age 13 weeks.

Oral typhoid and yellow fever vaccines are not known to be affected by the administration of immune globulin or blood products. This is because few North Americans are immune to yellow fever or typhoid. Consequently, donated blood products in the United States do not contain a significant amount of antibody to these organisms. Typhoid and yellow fever vaccines may be given simultaneously with blood products, or separated by any interval. The replication of live attenuated influenza vaccine (LAIV) is not believed to be affected by antibody-containing blood products. LAIV can be given any time before, during or after administration of antibody-containing blood products.

Products Containing Type-Specific or Negligible Antibody

Some blood products do not contain antibodies that interfere with vaccine replication. Palivizumab (Synagis), used for the prevention of respiratory syncytial virus (RSV) infection in infants and young children, contains antibody directed only at RSV. Washed red blood cells contain a negligible amount of antibody. These products can be given anytime before, during or after administration of MMR or varicella-containing vaccines.

Simultaneous and Nonsimultaneous Administration

Simultaneous administration (that is, administration at the same visit) of the most widely used live and inactivated vaccines does not result in decreased antibody responses or increased rates of adverse reaction. Simultaneous administration of all vaccines for which a child is eligible is very important in childhood vaccination programs because it increases the probability that a child will be fully immunized at the appropriate age. A study during a measles outbreak in the early 1990s showed that about one-third of measles cases in unvaccinated but vaccine-eligible preschool children could have been prevented if MMR had been administered at the same visit when another vaccine was given.
Although all indicated vaccines should be administered at the same visit, individual vaccines should not be mixed in the same syringe unless they are licensed for mixing by the Food and Drug Administration. Only the sanofi-pasteur Hib/DTaP (TriHIBit) vaccine is licensed for mixing in the same syringe. See Appendix D for additional guidelines for vaccine administration.

**Nonsimultaneous Administration of Different Vaccines**

In some situations, vaccines that could be given at the same visit are not. If live parenteral (injected) vaccines (MMR, MMRV, varicella, zoster, and yellow fever) and live intranasal influenza vaccine (LAIV) are not administered at the same visit, they should be separated by at least 4 weeks. This interval is intended to reduce or eliminate interference from the vaccine given first on the vaccine given later. If two live parenteral vaccines or LAIV are not administered on the same day but are separated by less than 4 weeks, the vaccine given second should be repeated in 4 weeks or confirmed to have been effective by serologic testing of the recipient (serologic testing is not recommended following LAIV, varicella, or zoster vaccines). An exception to this recommendation is yellow fever vaccine administered less than 4 weeks after single-antigen measles vaccine. A 1999 study demonstrated that yellow fever vaccine is not affected by measles vaccine given 1–27 days earlier. The effect of nonsimultaneously administered rubella, mumps, varicella, zoster, LAIV and yellow fever vaccines is not known.

Live vaccines administered by the oral route (oral polio vaccine [OPV], oral typhoid, and rotavirus) are not believed to interfere with each other if not given simultaneously. These vaccines may be given at any time before or after each other. Rotavirus vaccine is not approved for children older than 32 weeks, oral typhoid is not approved for children younger than 6 years of age, and OPV is no longer available in the United States, so these vaccines are not likely to be given to the same child.

Parenteral live vaccines (MMR, MMRV, varicella, zoster, and yellow fever) and LAIV are not believed to have an effect on live vaccines given by the oral route (OPV, oral typhoid, and rotavirus). Live oral vaccines may be given at any time before or after live parenteral vaccines or LAIV.

All other combinations of two inactivated vaccines, or live and inactivated vaccines, may be given at any time before or after each other.
General Recommendations on Immunization

Interval Between Doses of the Same Vaccine

**GENERAL RULE**

Increasing the interval between doses of a multidose vaccine does not diminish the effectiveness of the vaccine.

Decreasing the interval between doses of a multidose vaccine may interfere with antibody response and protection.

Immunizations are recommended for members of the youngest age group at risk for a disease for whom efficacy and safety of a vaccine have been demonstrated. Most vaccines in the childhood immunization schedule require two or more doses for development of an adequate and persisting antibody response. Studies have demonstrated that recommended ages and intervals between doses of the same antigen(s) provide optimal protection or have the best evidence of efficacy. Table 1 of the General Recommendations on Immunization (included in Appendix A) shows the recommended and minimal ages and intervals between doses of vaccines most frequently used in the United States.

Administering doses of a multidose vaccine at shorter than the recommended intervals might be necessary when an infant or child is behind schedule and needs to be brought up-to-date quickly or when international travel is pending. In these cases, an accelerated schedule using the minimum age or minimum interval criteria can be used. Accelerated schedules should not be used routinely.

Vaccine doses should not be administered at intervals less than the recommended minimal intervals or earlier than the minimal ages. Two exceptions to this may occur. The first is for measles vaccine during a measles outbreak, when the vaccine may be administered at an age younger than 12 months (this dose would not be counted, and should be repeated at 12 months of age or older). The second exception involves administering a dose a few days earlier than the minimum interval or age, which is unlikely to have a substantially negative effect on the immune response to that dose. Although vaccinations should not be scheduled at an interval or age less than the recommended minimums, a child may have erroneously been brought to the office early, or may have come for an appointment not specifically for vaccination. In these situations, the clinician can consider administering the vaccine earlier than the minimum interval or age. If the parent/child is known to the clinician and is reliable, it is preferable to reschedule the child for vaccination closer to the recommended interval. If the parent/child is not known to the clinician or is not reliable...
(e.g., habitually misses appointments), it may be preferable to administer the vaccine at that visit than to reschedule a later appointment that may not be kept.

Vaccine doses administered up to 4 days before the minimum interval or age can be counted as valid. This 4-day recommendation does not apply to rabies vaccine because of the unique schedule for this vaccine. Doses administered 5 days or earlier than the minimum interval or age should not be counted as valid doses and should be repeated as age appropriate. The repeat dose should generally be spaced after the invalid dose by an interval at least equal to the recommended minimum interval shown in Table 1 of the General Recommendations. In certain situations, local or state requirements might mandate that doses of selected vaccines be administered on or after specific ages, superseding this 4-day “grace period.”

In some cases, a scheduled dose of vaccine may not be given on time. If this occurs, the dose should be given at the next visit. Not all permutations of all schedules for all vaccines have been studied. However, available data indicate that intervals between doses longer than those routinely recommended do not affect seroconversion rate or titer when the schedule is completed. Consequently, it is not necessary to restart the series or add doses because of an extended interval between doses. The only exception to this rule is oral typhoid vaccine in some circumstances. Some experts recommend repeating the series of oral typhoid vaccine if the four-dose series is extended to more than 3 weeks.

### Number of Doses

For live injected vaccines, the first dose administered at the recommended age usually provides protection. An additional dose is given to ensure seroconversion. For instance, 95%–98% of recipients will respond to a single dose of measles vaccine. The second dose is given to ensure that nearly 100% of persons are immune (i.e., the second dose is “insurance”). Immunity following live vaccines is long-lasting, and booster doses are not necessary.

For inactivated vaccines, the first dose administered at the recommended age usually does not provide protection (hepatitis A vaccine is an exception). A protective immune response may not develop until the second or third dose. For inactivated vaccines, antibody titers may decrease (wane) below protective levels after a few years. This phenomenon is most notable for tetanus and diphtheria. For these vaccines, periodic “boosting” is required. An additional dose is given to raise antibody back to protective levels.
Not all inactivated vaccines require boosting throughout life. For example, *Haemophilus influenzae* type b (Hib) vaccine does not require boosting because Hib disease is very rare in children older than 5 years of age. Hepatitis B vaccine does not require boosting because of immunologic memory to the vaccine and the long incubation period of hepatitis B (which can produce an "autoboost").

**Adverse Reactions Following Vaccination**

Vaccines are intended to produce active immunity to specific antigens. An adverse reaction is an untoward effect caused by a vaccine that is extraneous to the vaccine’s primary purpose of producing immunity. Adverse reactions are also called vaccine side effects. A vaccine adverse event refers to any medical event that occurs following vaccination. An adverse event could be a true adverse reaction or just a coincidental event, with further research needed to distinguish between them.

Vaccine adverse reactions fall into three general categories: local, systemic, and allergic. Local reactions are generally the least severe and most frequent. Allergic reactions are the most severe and least frequent.

The most common type of adverse reactions are local reactions, such as pain, swelling, and redness at the site of injection. Local reactions may occur with up to 80% of vaccine doses, depending on the type of vaccine. Local reactions are most common with inactivated vaccines, particularly those, such as DTaP, that contain an adjuvant. Local adverse reactions generally occur within a few hours of the injection and are usually mild and self-limited. On rare occasions, local reactions may be very exaggerated or severe. These are often referred to as hypersensitivity reactions, although they are not allergic, as the term implies. These reactions are also known as Arthus reactions, and are most commonly seen with tetanus and diphtheria toxoids. Arthus reactions are believed to be due to very high titers of antibody, usually caused by too many doses of toxoid.

Systemic adverse reactions are more generalized events and include fever, malaise, myalgias (muscle pain), headache, loss of appetite, and others. These symptoms are common and nonspecific; they may occur in vaccinated persons because of the vaccine or may be caused by something unrelated to the vaccine, like a concurrent viral infection, stress, or excessive alcohol consumption.

Systemic adverse reactions were relatively frequent with DTP vaccine, which contained a whole-cell pertussis com-
ponent. However, comparison of the frequency of systemic adverse events among vaccine and placebo recipients shows they are less common with inactivated vaccines currently in use, including acellular pertussis vaccine.

Systemic adverse reactions may occur following receipt of live attenuated vaccines. Live attenuated vaccines must replicate in order to produce immunity. The adverse reactions that follow live attenuated vaccines, such as fever or rash, represent symptoms produced from viral replication and are similar to a mild form of the natural disease. Systemic adverse reactions following live vaccines are usually mild, and occur 7–21 days after the vaccine was given (i.e., after an incubation period of the vaccine virus). LAIV replicates in the mucous membranes of the nose and throat, not in the lung. As a result, LAIV may cause upper respiratory symptoms (like a cold) but not influenza-like symptoms.

A third type of vaccine adverse reaction is a severe (anaphylactic) allergic reaction. The allergic reaction may be caused by the vaccine antigen itself or some other component of the vaccine, such as cell culture material, stabilizer, preservative, or antibiotic used to inhibit bacterial growth. Severe allergic reactions may be life-threatening. Fortunately, they are rare, occurring at a rate of less than one in half a million doses. The risk of an allergic reaction can be minimized by good screening prior to vaccination. All providers who administer vaccines must have an emergency protocol and supplies to treat anaphylaxis.

**Reporting Vaccine Adverse Events**

From 1978 to 1990, CDC conducted the Monitoring System for Adverse Events Following Immunization (MSAEFI) in the public sector. In 1990, MSAEFI was replaced by the Vaccine Adverse Event Reporting System (VAERS), which includes reporting from both public and private sectors. Providers should report any clinically significant adverse event that occurs after the administration of any vaccine licensed in the United States.

Providers should report a clinically significant adverse event even if they are unsure whether a vaccine caused the event. The telephone number to call for answers to questions and to obtain VAERS forms is (800) 822-7967, or visit the VAERS website at http://vaers.hhs.gov. VAERS now accepts reports of adverse reactions through their online system. (See Chapter 4, Vaccine Safety.)

**Contraindications and Precautions to Vaccination**

Contraindications and precautions to vaccination generally dictate circumstances when vaccines will not be given. Most
contraindications and precautions are temporary, and the vaccine can be given at a later time.

A contraindication is a condition in a recipient that greatly increases the chance of a serious adverse reaction. It is a condition in the recipient of the vaccine, not with the vaccine per se. If the vaccine were given in the presence of that condition, the resulting adverse reaction could seriously harm the recipient. For instance, administering influenza vaccine to a person with a true anaphylactic allergy to egg could cause serious illness or death in the recipient. In general, vaccines should not be administered when a contraindication condition is present.

A precaution is similar to a contraindication. A precaution is a condition in a recipient that might increase the chance or severity of a serious adverse reaction, or that might compromise the ability of the vaccine to produce immunity (such as administering measles vaccine to a person with passive immunity to measles from a blood transfusion). Injury could result, but the chance of this happening is less than with a contraindication. In general, vaccines are deferred when a precaution condition is present. However, situations may arise when the benefit of protection from the vaccine outweighs the risk of an adverse reaction, and a provider may decide to give the vaccine. For example, prolonged crying or a high fever after a dose of whole-cell or acellular pertussis vaccine is considered to be a precaution to subsequent doses of pediatric pertussis vaccine. But if the child were at high risk of pertussis exposure (e.g., during a pertussis outbreak in the community), a provider may choose to vaccinate the child and treat the adverse reaction if it occurs. In this example, the benefit of protection from the vaccine outweighs the harm potentially caused by the vaccine.

There are very few true contraindication and precaution conditions. Only two of these conditions are generally considered to be permanent: severe (anaphylactic) allergic reaction to a vaccine component or following a prior dose of a vaccine, and encephalopathy not due to another identifiable cause occurring within 7 days of pertussis vaccination.

Conditions considered permanent precautions to further doses of pediatric pertussis-containing vaccine are temperature of 105°F or higher within 48 hours of a dose, collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours of a dose, persistent inconsolable crying lasting 3 or more hours occurring within 48 hours of a dose, or a seizure, with or without fever, occurring within 3 days of a dose. The occurrence of one of these events in a child following DTaP vaccine is not a precaution to later vaccination with the adolescent/adult formulation of pertussis vaccine (Tdap).
Two conditions are temporary contraindications to vaccination with live vaccines: pregnancy and immunosuppression. Two conditions are temporary precautions to vaccination: moderate or severe acute illness (all vaccines), and recent receipt of an antibody-containing blood product. The latter precaution applies only to MMR, varicella-containing (except zoster) and rotavirus vaccines.

**Allergy**

A severe (anaphylactic) allergic reaction following a dose of vaccine will almost always contraindicate a subsequent dose of that vaccine. Severe allergies are those that are mediated by IgE, occur within minutes or hours of receiving the vaccine, and require medical attention. Examples of symptoms and signs typical of severe allergic reactions are generalized urticaria (hives), swelling of the mouth and throat, difficulty breathing, wheezing, hypotension, or shock. With appropriate screening these reactions are very rare following vaccination.

A table listing vaccine contents is included in Appendix B. Persons may be allergic to the vaccine antigen or to a vaccine component such as animal protein, antibiotic, preservative, or stabilizer. The most common animal protein allergen is egg protein found in vaccines prepared using embryonated chicken eggs (e.g., yellow fever and influenza vaccines). Ordinarily, a person who can eat eggs or egg products can receive vaccines that contain egg; persons with histories of anaphylactic or anaphylactic-like allergy to eggs or egg proteins should not. Asking persons whether they can eat eggs without adverse effects is a reasonable way to screen for those who might be at risk from receiving yellow fever and influenza vaccines.

Several recent studies have shown that children who have a history of severe allergy to eggs rarely have reactions to MMR vaccine. This is probably because measles and mumps vaccine viruses are both grown in chick embryo fibroblasts, not actually in eggs. It appears that gelatin, not egg, might be the cause of allergic reactions to MMR. As a result, in 1998, the ACIP removed severe egg allergy as a contraindication to measles and mumps vaccines. Egg-allergic children may be vaccinated with MMR without prior skin testing.

Certain vaccines contain trace amounts of neomycin. Persons who have experienced an anaphylactic reaction to neomycin should not receive these vaccines. Most often, neomycin allergy presents as contact dermatitis, a manifestation of a delayed-type (cell-mediated) immune response, rather than anaphylaxis. A history of delayed-type reactions to neomycin is not a contraindication for administration of vaccines that contain neomycin.

Latex is sap from the commercial rubber tree. Latex contains naturally occurring impurities (e.g., plant proteins and peptides),
which are believed to be responsible for allergic reactions. Latex is processed to form natural rubber latex and dry natural rubber. Dry natural rubber and natural rubber latex might contain the same plant impurities as latex but in lesser amounts. Natural rubber latex is used to produce medical gloves, catheters, and other products. Dry natural rubber is used in syringe plungers, vial stoppers, and injection ports on intravascular tubing. Synthetic rubber and synthetic latex also are used in medical gloves, syringe plungers, and vial stoppers. Synthetic rubber and synthetic latex do not contain natural rubber or natural latex, and therefore, do not contain the impurities linked to allergic reactions.

The most common type of latex sensitivity is contact-type (type 4) allergy, usually as a result of prolonged contact with latex-containing gloves. However, injection-procedure–associated latex allergies among diabetic patients have been described. Allergic reactions (including anaphylaxis) after vaccination procedures are rare. Only one report of an allergic reaction after administration of hepatitis B vaccine in a patient with known severe allergy (anaphylaxis) to latex has been published.

If a person reports a severe (anaphylactic) allergy to latex, vaccines supplied in vials or syringes that contain natural rubber should not be administered unless the benefit of vaccination clearly outweighs the risk of an allergic reaction to the vaccine. For latex allergies other than anaphylactic allergies (e.g., a history of contact allergy to latex gloves), vaccines supplied in vials or syringes that contain dry natural rubber or natural rubber latex can be administered.

**Pregnancy**

The concern with vaccination of a pregnant woman is infection of the fetus and is theoretical. Only smallpox (vaccinia) vaccine has been shown to cause fetal injury. However, since the theoretical possibility exists, live vaccines should not be administered to women known to be pregnant.

Since inactivated vaccines cannot replicate, they cannot cause fetal infection. In general, inactivated vaccines may be administered to pregnant women for whom they are indicated. An exception is human papillomavirus (HPV) vaccine, which should be deferred during pregnancy because of a lack of safety and efficacy data for this vaccine in pregnant women.

Pregnant women are at increased risk of complications of influenza. Any woman who will be pregnant during influenza season (generally December through March) should receive inactivated influenza vaccine. Pregnant women should not receive live attenuated influenza vaccine.

---

**Vaccination of Pregnant Women**

- Live vaccines should not be administered to women known to be pregnant
- In general inactivated vaccines may be administered to pregnant women for whom they are indicated
- HPV vaccine should be deferred during pregnancy
Any woman who might become pregnant is encouraged to receive a single dose of Tdap if she has not already received a dose. Women who have not received Tdap should receive a dose in the immediate postpartum period, before discharge from the hospital or birthing center.

ACIP recommends Td when tetanus and diphtheria protection is required during pregnancy. However, pregnancy is not a contraindication for use of Tdap. A clinician may choose to administer Tdap to a pregnant woman in certain circumstances, such as during a community pertussis outbreak. When Td or Tdap is administered during pregnancy, the second or third trimester is preferred to avoid coincidental association of vaccination and spontaneous termination of a pregnancy, which is more common in the first trimester. Clinicians can choose to administer Tdap instead of Td to protect against pertussis in pregnant adolescents for routine or “catch-up” vaccination because the incidence of pertussis is high among adolescents. They also may consider Tdap for pregnant healthcare personnel and child care providers to prevent transmission to infants younger than 12 months of age and other vulnerable persons, and for pregnant women employed in an institution or living in a community with increased pertussis activity.

Susceptible household contacts of pregnant women should receive MMR and varicella vaccines, and may receive LAIV, zoster and rotavirus vaccines if they are otherwise eligible.

**Immunosuppression**

Live vaccines can cause severe or fatal reactions in immunosuppressed persons due to uncontrolled replication of the vaccine virus. Live vaccines should not be administered to severely immunosuppressed persons for this reason. Persons with isolated B-cell deficiency may receive varicella vaccine. Inactivated vaccines cannot replicate, so they are safe to use in immunosuppressed persons. However, response to the vaccine may be decreased.

Both diseases and drugs can cause significant immunosuppression. Persons with congenital immunodeficiency, leukemia, lymphoma, or generalized malignancy should not receive live vaccines. OPV should not be given if an immunosuppressed person is in the household. However, MMR, varicella vaccines, and LAIV may be given when an immunosuppressed person lives in the same house. Household contacts of immunosuppressed persons may receive zoster vaccine if indicated. Transmission has not been documented from a person who received herpes zoster vaccine.

Certain drugs may cause immunosuppression. For instance, persons receiving cancer treatment with alkylating agents...
or antimetabolites, or radiation therapy should not be given live vaccines. Live vaccines can be given after chemotherapy has been discontinued for at least 3 months. Persons receiving large doses of corticosteroids should not receive live vaccines. For example, this would include persons receiving 20 milligrams or more of prednisone daily or 2 or more milligrams of prednisone per kilogram of body weight per day for 14 days or longer.

Aerosolized steroids, such as inhalers for asthma, are not contraindications to vaccination, nor are alternate-day, rapidly tapering, and short (less than 14 days) high-dose schedules, topical formulations, and physiologic replacement schedules.

The safety and efficacy of live attenuated vaccines administered concurrently with recombinant human immune mediators and immune modulators are not known. There is evidence that use of therapeutic monoclonal antibodies, especially the anti–tumor necrosis factor agents adalimumab, infliximab, and etanercept, may lead to reactivation of latent tuberculosis infection and tuberculosis disease and predispose to other opportunistic infections. Because the safety of live attenuated vaccines for persons receiving these drugs is not known, it is prudent to avoid administration of live attenuated vaccines for at least a month following treatment with these drugs.

Inactivated vaccines may be administered to immunosuppressed persons. Certain vaccines are recommended or encouraged specifically because immunosuppression is a risk factor for complications from vaccine-preventable diseases (i.e., influenza, invasive pneumococcal disease, invasive meningococcal disease, invasive Haemophilus influenzae type b disease, and hepatitis B). However, response to the vaccine may be poor depending on the degree of immunosuppression present. Because a relatively functional immune system is required to develop an immune response to a vaccine, an immunosuppressed person may not be protected even if the vaccine has been given. Additional recommendations for vaccination of immunosuppressed persons are detailed in the General Recommendations on Immunization.

**HIV Infection**

Persons infected with human immunodeficiency virus (HIV) may have no symptoms, or they may be severely immunosuppressed. In general, the same vaccination recommendations apply as with other types of immunosuppression. Live-virus vaccines are usually contraindicated, but inactivated vaccines may be administered if indicated.
Varicella and measles can be very severe illnesses in persons with HIV infection and are often associated with complications. Varicella vaccine is recommended for children (but not adults) with HIV infection who are not severely immunosuppressed. Zoster vaccine should not be given to persons with AIDS or clinical manifestations of HIV infection. Measles vaccine (as combination MMR vaccine) is recommended for persons with HIV infection who are asymptomatic or mildly immunosuppressed. However, persons with severe immunosuppression due to HIV infection should not receive measles vaccine or MMR. MMRV should not be administered to persons with HIV infection. Persons with HIV infection should not receive LAIV; they should receive inactivated influenza vaccine (TIV). Data are insufficient from clinical trials to support administration of rotavirus vaccine to infants with indeterminate HIV status who are born to mothers with HIV/AIDS. Yellow fever vaccine should be considered for persons who do not have AIDS or other symptomatic manifestations of HIV infection, who have established laboratory verification of adequate immune system function, and who cannot avoid potential exposure to yellow fever virus.

Susceptible household contacts of persons with HIV infection should receive MMR and varicella vaccines, and may receive rotavirus, zoster and LAIV vaccines if otherwise eligible.

**Vaccination of Hematopoietic Stem Cell Transplant Recipients**

Hematopoietic stem cell transplant (HSCT) is the infusion of hematopoietic stem cells from a donor into a patient who has received chemotherapy and often radiation, both of which are usually bone marrow ablative. HSCT is used to treat a variety of neoplastic diseases, hematologic disorders, immunodeficiency syndromes, congenital enzyme deficiencies, and autoimmune disorders. HSCT recipients can receive either their own cells (i.e., autologous HSCT) or cells from a donor other than the transplant recipient (i.e., allogeneic HSCT).

Antibody titers to vaccine-preventable diseases (e.g., tetanus, poliovirus, measles, mumps, rubella, and encapsulated bacteria [i.e., Streptococcus pneumoniae and Haemophilus influenzae type b]) decline during the 1–4 years after allogeneic or autologous HSCT if the recipient is not revaccinated. HSCT recipients are at increased risk for certain vaccine-preventable diseases. As a result, HSCT recipients should be routinely revaccinated after HSCT, regardless of the source of the transplanted stem cells. Revaccination with inactivated vaccines should begin 12 months after HSCT. An exception to this recommendation is influenza vaccine, which should be administered 6 months after HSCT and annually thereafter for the life of the recipient. Revaccination with pneumococcal conjugate vaccine (PCV) can be considered,
especially if the HSCT recipient is younger than 60 months. Two doses of PCV followed by a dose of pneumococcal polysaccharide vaccine (at least 8 weeks after the second dose of PCV) are recommended.

MMR and varicella vaccines should be administered 24 months after transplantation if the HSCT recipient is presumed to be immunocompetent. Meningococcal and Tdap vaccines are not currently recommended for HSCT recipients because of insufficient experience using these vaccines among HSCT recipients.

Household and other close contacts of HSCT recipients and healthcare providers who care for HSCT recipients should be appropriately vaccinated, particularly against influenza, measles, and varicella. Additional details of vaccination of HSCT recipients and their contacts can be found in a CDC report on this topic available at http://www.cdc.gov/vaccines/pubs/textbks-manuals-guides.htm.

**Moderate or Severe Acute Illness**
There is no evidence that a concurrent acute illness reduces vaccine efficacy or increases vaccine adverse events. The concern is that an adverse event (particularly fever) following vaccination could complicate the management of a severely ill person. If a person has a moderate or severe acute illness, vaccination with both live and inactivated vaccines should be delayed until the illness has improved.

**Invalid Contraindications to Vaccination**
Some healthcare providers inappropriately consider certain conditions or circumstances to be true contraindications or precautions to vaccinations. Such conditions or circumstances are known as invalid contraindications; they result in missed opportunities to administer needed vaccines. Some of the most common invalid contraindications are mild illnesses, conditions related to pregnancy and breastfeeding, allergies that are not anaphylactic in nature, and certain aspects of the patient’s family history.

**Mild Illness**
Children with mild acute illnesses, such as low-grade fever, upper respiratory infection (URI), colds, otitis media, and mild diarrhea, should be vaccinated on schedule. Several large studies have shown that young children with URI, otitis media, diarrhea, and/or fever respond to measles vaccine as well as those without these conditions. There is no evidence that mild diarrhea reduces the success of immunization of infants in the United States.
General Recommendations on Immunization

Low-grade fever is not a contraindication to immunization. Temperature measurement is not necessary before immunization if the infant or child does not appear ill and the parent does not say the child is currently ill. ACIP has not defined a body temperature above which vaccines should not be administered. The decision to vaccinate should be based on the overall evaluation of the person rather than an arbitrary body temperature.

Antimicrobial Therapy
Antibiotics do not have an effect on the immune response to most vaccines. The manufacturer advises that Ty21a oral typhoid vaccine should not be administered to persons receiving sulfonamides or other antibiotics; Ty21a should be administered at least 24 hours after a dose of an antibacterial drug.

No commonly used antimicrobial drug will inactivate a live-virus vaccine. However, antiviral drugs may affect vaccine replication in some circumstances. Live attenuated influenza vaccine should not be administered until 48 hours after cessation of therapy using antiviral drugs active against influenza (amantadine, rimantadine, zanamivir, oseltamivir). Antiviral drugs active against herpesviruses (acyclovir, famciclovir) should be discontinued 24 hours before administration of a varicella-containing vaccine, if possible.

Disease Exposure or Convalescence
If a person is not moderately or severely ill, he or she should be vaccinated. There is no evidence that either disease exposure or convalescence will affect the response to a vaccine or increase the likelihood of an adverse event.

Pregnant or Immunosuppressed Person in the Household
It is critical that healthy household contacts of pregnant women and immunosuppressed persons be vaccinated. Vaccination of healthy contacts reduces the chance of exposure of pregnant women and immunosuppressed persons. Most vaccines, including live vaccines (MMR, varicella, zoster, rotavirus, LAIV, and yellow fever) can be administered to infants or children who are household contacts of pregnant or immunosuppressed persons, as well as to breastfeeding infants (where applicable). Vaccinia (smallpox) vaccine should not be administered to household contacts of a pregnant or immunosuppressed person in a nonemergency situation. Live attenuated influenza vaccine should not be administered to persons who have contact with severely immunosuppressed persons who are hospitalized and require care in a protected environment (i.e., who are in isolation because of immunosuppression). LAIV may be administered to contacts of persons with lesser degrees of immunosuppression.
General Recommendations on Immunization

Measles and mumps vaccine viruses produce a noncommunicable infection and are not transmitted to household contacts. Rubella vaccine virus has been shown to be shed in human milk, but transmission to an infant has rarely been documented. Transmission of varicella vaccine virus is not common, and most women and older immunosuppressed persons are immune from having had chickenpox as a child. Transmission of zoster vaccine virus to household or other close contacts has not been reported.

Breastfeeding
Breastfeeding does not decrease the response to routine childhood vaccines and is not a contraindication for any vaccine except smallpox. Breastfeeding also does not extend or improve the passive immunity to vaccine-preventable disease that is provided by maternal antibody except possibly for *Haemophilus influenzae* type b. Breastfed infants should be vaccinated according to recommended schedules. Although rubella vaccine virus might be shed in human milk, infection of an infant is rare. LAIV may be administered to a woman who is breastfeeding if she is otherwise eligible; the risk of transmission of vaccine virus is unknown but is probably low.

Preterm Birth
Vaccines should be started on schedule on the basis of the child’s chronological age. Preterm infants have been shown to respond adequately to vaccines used in infancy.

Studies demonstrate that decreased seroconversion rates might occur among preterm infants with very low birth weight (less than 2,000 grams) after administration of hepatitis B vaccine at birth. However, by 1 month chronological age, all preterm infants, regardless of initial birth weight or gestational age are as likely to respond as adequately as older and larger infants. All preterm infants born to hepatitis B surface antigen (HBsAg)–positive mothers and mothers with unknown HBsAg status must receive immunoprophylaxis with hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) within 12 hours after birth. If these infants weigh less than 2000 grams at birth, the initial vaccine dose should not be counted toward completion of the hepatitis B vaccine series, and three additional doses of hepatitis B vaccine should be administered beginning when the infant is 1 month of age.

Preterm infants with a birth weight of less than 2000 grams who are born to women documented to be HBsAg-negative at the time of birth should receive the first dose of the hepatitis B vaccine series at 1 month of chronological age or at the time of hospital discharge.
General Recommendations on Immunization

Allergy to Products Not Present in Vaccine
Infants and children with nonspecific allergies, duck or feather allergy, or allergy to penicillin, children who have relatives with allergies, and children taking allergy shots can and should be immunized. No vaccine available in the United States contains duck antigen or penicillin.

Allergy That is Not Anaphylactic
Anaphylactic allergy to a vaccine component (such as egg or neomycin) is a true contraindication to vaccination. If an allergy to a vaccine component is not anaphylactic, it is not a contraindication to that vaccine.

Family History of Adverse Events
The only family history that is relevant in the decision to vaccinate a child is immunosuppression. A family history of adverse reactions unrelated to immunosuppression or family history of seizures or sudden infant death syndrome (SIDS) is not a contraindication to vaccination. Varicella-containing vaccine (except zoster) should not be administered to persons who have a family history of congenital or hereditary immunodeficiency in first-degree relatives (e.g., parents and siblings) unless the immunocompetence of the potential vaccine recipient has been clinically substantiated or verified by a laboratory.

Tuberculin Skin Test
Infants and children who need a tuberculin skin test (TST) can and should be immunized. All vaccines, including MMR, can be given on the same day as a TST, or any time after a TST is applied. For most vaccines, there are no TST timing restrictions.

MMR vaccine may decrease the response to a TST, potentially causing a false-negative response in someone who actually has an infection with tuberculosis. MMR can be given the same day as a TST, but if MMR has been given and 1 or more days have elapsed, in most situations a wait of at least 4 weeks is recommended before giving a routine TST. No information on the effect of varicella-containing vaccine or LAIV on a TST is available. Until such information is available, it is prudent to apply rules for spacing measles vaccine and TST to varicella vaccine and LAIV.

Multiple Vaccines
As noted earlier in this chapter, administration at the same visit of all vaccines for which a person is eligible is critical.
General Recommendations on Immunization

to reaching and maintaining high vaccination coverage. All vaccines (except vaccinia) can be administered at the same visit as all other vaccines.

Screening for Contraindications and Precautions to Vaccination

The key to preventing serious adverse reactions is screening. Every person who administers vaccines should screen every patient for contraindications and precautions before giving the vaccine dose. Effective screening is not difficult or complicated and can be accomplished with just a few questions.

Is the child (or are you) sick today?
There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution, with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (such as otitis media, upper respiratory infections, and diarrhea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics.

Does the child have allergies to medications, food, or any vaccine?
A history of anaphylactic reaction such as hives (urticaria), wheezing or difficulty breathing, or circulatory collapse or shock (not fainting) from a previous dose of vaccine or vaccine component is a contraindication for further doses. For example, if a person experiences anaphylaxis after eating eggs, do not administer influenza vaccine. It may be more efficient to inquire about allergies in a generic way (i.e., any food or medication) rather than to inquire about specific vaccine components. Most parents will not be familiar with minor components of vaccine, but they should know if the child has had an allergic reaction to a food or medication that was severe enough to require medical attention.

Has the child had a serious reaction to a vaccine in the past?
A history of anaphylactic reaction to a previous dose of vaccine or vaccine component is a contraindication for subsequent doses. A history of encephalopathy within 7 days following DTP/DTaP is a contraindication for further doses of pertussis-containing vaccine. Precautions to DTaP (not Tdap) include (a) seizure within 3 days of a dose, (b) pale or limp episode or collapse within 48 hours of a dose, (c) continuous crying for 3 hours within 48 hours of a dose, and (d) fever of 105°F (40°C) within 48 hours of a previous dose. There are other adverse events that might have occurred following vaccination that constitute contraindications or precautions to future doses. Usually vaccines are deferred when a precaution is present. However, situations may arise
when the benefit outweighs the risk (e.g., during a
community pertussis outbreak). A local reaction (redness
or swelling at the site of injection) is not a contraindication
to subsequent doses.

**Has the child had a seizure, or brain or nerve problem?**
DTaP and Tdap are contraindicated for children who have
a history of encephalopathy within 7 days following DTP/
DTaP. An unstable progressive neurologic problem is a
precaution to the use of DTaP and Tdap. For children with
stable neurologic disorders (including seizures) unrelated to
vaccination, or for children with a family history of seizure,
vaccinate as usual but consider the use of acetaminophen or
ibuprofen to minimize fever.

A history of Guillain-Barré syndrome is a precaution for
tetanus-containing, influenza and meningococcal conjugate
vaccines.

**Has the child had a health problem with asthma, lung
disease, heart disease, kidney disease, metabolic disease
such as diabetes, or a blood disorder?**
Children with any of these conditions should not receive
LAIV. Children with these conditions should receive
inactivated influenza vaccine only.

**Does the child have cancer, leukemia, AIDS, or any other
immune system problem?**
Live-virus vaccines (e.g., MMR, varicella, rotavirus, and
the intranasal live attenuated influenza vaccine [LAIV]) are
usually contraindicated in immunocompromised children.
However, there are exceptions. For example, MMR and
varicella vaccines are recommended for asymptomatic
HIV-infected children who do not have evidence of severe
immunosuppression. Persons with severe immunosuppression
should not receive MMR, varicella, rotavirus, or LAIV
vaccines. For details, consult the ACIP recommendations
for each vaccine.

**Has the child taken cortisone, prednisone, other
steroids, or anticancer drugs, or had x-ray treatments
in the past 3 months?**
Live-virus vaccines (e.g., MMR, varicella, zoster, LAIV)
should be postponed until after chemotherapy or long-term,
high-dose steroid therapy has ended. Details and the length
of time to postpone vaccination are described elsewhere
in this chapter and in the General Recommendations on
Immunization.
General Recommendations on Immunization

Has the child received a transfusion of blood or blood products, or been given a medicine called immune ( gamma) globulin in the past year?
Certain live virus vaccines (e.g., MMR, varicella, rotavirus) may need to be deferred, depending on the type of blood product and the interval since the blood product was administered. Information on recommended intervals between immune globulin or blood product administration and MMR or varicella vaccination is in Appendix A and in the General Recommendations on Immunization.

Is the child/teen pregnant or is there a chance she could become pregnant during the next month?
Live-virus vaccines (e.g., MMR, varicella, zoster, LAIV) are contraindicated during pregnancy because of the theoretical risk of virus transmission to the fetus. Sexually active young women who receive MMR or varicella vaccination should be instructed to practice careful contraception for 1 month following receipt of either vaccine. On theoretical grounds, inactivated poliovirus vaccine should not be given during pregnancy; however, it may be given if the risk of exposure is imminent (e.g., travel to endemic-disease areas) and immediate protection is needed. Use of Td or Tdap is not contraindicated in pregnancy. At the provider’s discretion, either vaccine may be administered during the second or third trimester.

Has the child received vaccinations in the past 4 weeks?
If the child was given either live attenuated influenza vaccine or an injectable live-virus vaccine (e.g., MMR, varicella, yellow fever) in the past 4 weeks, he or she should wait 28 days before receiving another live vaccine. Inactivated vaccines may be given at the same time or at any time before or after a live vaccine.

Every person should be screened for contraindications and precautions before vaccination. Standardized screening forms for both children and adults have been developed by the Immunization Action Coalition and are available on their web site at http://www.immunize.org.

ACKNOWLEDGMENT
The editors thank Dr. Andrew Kroger, National Center for Immunization and Respiratory Diseases, CDC, for his assistance in updating this chapter.
Selected References


